Aspectos clínicamente relevantes para pacientes diabéticos en tratamiento con insulina: prevención de hipoglucemias y flexibilidad en la administración

Coffey, 2002, Valuing health-related quality of life in diabetes, Diabetes Care, 25, 2238, 10.2337/diacare.25.12.2238 Peyrot, 2010, Correlates of insulin injection omission, Diabetes Care, 33, 240, 10.2337/dc09-1348 Rubin, 1992, Psychosocial problems and interventions in diabetes. A review of the literature, Diabetes Care, 15, 1640, 10.2337/diacare.15.11.1640 Bott, 1994, Predictors of glycaemic control in type1 diabetic patients after participation in an intensified treatment and teaching programme, Diabet Med, 11, 362, 10.1111/j.1464-5491.1994.tb00287.x Bradley, 1994, Guidelines for encouraging psychological well-being: Report of a Working Group of the World Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes, Diabet Med, 11, 510, 10.1111/j.1464-5491.1994.tb00316.x Bott, 1998, Validation of a diabetes-specific quality-of-life scale for patients with type1 diabetes, Diabetes Care, 21, 757, 10.2337/diacare.21.5.757 Bron, 2012, Hypoglycemia, treatment discontinuation, and costs in patients with type2 diabetes mellitus on oral antidiabetic drugs, Postgrad Med, 124, 124, 10.3810/pgm.2012.01.2525 Seaquist, 2013, Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society, Diabetes Care, 36, 1384, 10.2337/dc12-2480 2007, Risk of hypoglycaemia in types1 and 2 diabetes: Effects of treatment modalities and their duration, Diabetologia, 50, 1140, 10.1007/s00125-007-0599-y Donnelly, 2005, Frequency and predictors of hypoglycaemia in type1 and insulin-treated type2 diabetes: A population-based study, Diabet Med, 22, 749, 10.1111/j.1464-5491.2005.01501.x Holstein, 2002, Incidence and costs of severe hypoglycemia, Diabetes Care, 25, 2109, 10.2337/diacare.25.11.2109 Marrett, 2011, Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type2 diabetes treated with oral antihyperglycemic agents: A survey study, BMC Res Notes, 4, 251, 10.1186/1756-0500-4-251 Ampudia-Blasco, 2009, Síndrome de falta de reconocimiento de la hipoglucemia. Factores de riesgo y tratamiento, Av Diabetol, 25, 280 Cranston, 1994, Restoration of hypoglycemia awareness in patients with long-duration insulin-dependent diabetes, Lancet, 344, 283, 10.1016/S0140-6736(94)91336-6 Fanelli, 1994, Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM, Diabetologia, 37, 1265, 10.1007/BF00399801 White, 1983, Identification of type1 diabetic patients at increased risk for hypoglycemia during intensive therapy, N Engl J Med, 308, 485, 10.1056/NEJM198303033080903 Perantie, 2008, Effects of prior hypoglycemia and hyperglycemia on cognition in children with type1 diabetes mellitus, Pediatr Diabetes, 9, 87, 10.1111/j.1399-5448.2007.00274.x Jacobson, 2007, Long-term effect of diabetes and its treatment on cognitive function, N Engl J Med, 356, 1842, 10.1056/NEJMoa066397 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, 329, 977, 10.1056/NEJM199309303291401 2008, Effects of intensive glucose lowering in type2 diabetes, N Engl J Med, 258, 2545 2008, Intensive blood glucose control and vascular outcomes in patients with type2 diabetes, N Engl J Med, 358, 2560, 10.1056/NEJMoa0802987 Duckworth, 2009, Glucose control and vascular complications in veterans with type2 diabetes, N Engl J Med, 360, 129, 10.1056/NEJMoa0808431 Zoungas, 2010, Severe hypoglycemia and risks of vascular events and death, N Engl J Med, 363, 1410, 10.1056/NEJMoa1003795 Bremer, 2009, Hypoglycemia unawareness in older compared with middle-aged patients with type2 diabetes, Diabetes Care, 32, 1513, 10.2337/dc09-0114 Whitmer, 2009, Hypoglycemic episodes and risk of dementia in older patients with type2 diabetes mellitus, Lancet, 301, 1565 Barendse, 2012, The impact of hypoglycaemia on quality of life and related patient-reported outcomes in type2 diabetes: A narrative review, Diabet Med, 29, 293, 10.1111/j.1464-5491.2011.03416.x King, 1998, Well-being, cerebral function, and physical fatigue after nocturnal hypoglycemia in IDDM, Diabetes Care, 21, 341, 10.2337/diacare.21.3.341 Gold, 1995, Hypoglycemia-induced cognitive dysfunction in diabetes mellitus: Effect of hypoglycemia unawareness, Physiol Behav, 58, 501, 10.1016/0031-9384(95)00085-W Davis, 2005, Impact of hypoglycaemia on quality of life and productivity in type1 and type2 diabetes, Curr Med Res Opin, 21, 1477, 10.1185/030079905X61929 Cox, 2000, Progressive hypoglycemia's impact on driving simulation performance. Occurrence, awareness and correction, Diabetes Care, 23, 163, 10.2337/diacare.23.2.163 Mühlhauser, 1995, Liberalized diet in patients with type1 diabetes, J Intern Med, 237, 591, 10.1111/j.1365-2796.1995.tb00890.x Sämann, 2005, Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type1 diabetes: A prospective implementation study, Diabetologia, 48, 1965, 10.1007/s00125-005-1905-1 Fanelli, 1993, Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM, Diabetes, 42, 1683, 10.2337/diab.42.11.1683 Menéndez Torre, 2012, Recomendaciones 2012 de la Sociedad Española de Diabetes sobre la utilización de tiras reactivas para la medición de la glucemia capilar en personas con diabetes, Av Diabetol, 28, 3, 10.1016/j.avdiab.2012.01.002 Anderson JHJr, 1997, Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group, Diabetes, 46, 265, 10.2337/diab.46.2.265 Raskin, 2000, Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type1 diabetes, Diabetes Care, 23, 583, 10.2337/diacare.23.5.583 Lalli, 1999, Long-term intensive treatment of type1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime, Diabetes Care, 22, 468, 10.2337/diacare.22.3.468 Rossetti, 2003, Intensive replacement of basal insulin in patients with type1 diabetes given rapid-acting insulin analog at mealtime: A 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime, Diabetes Care, 26, 1490, 10.2337/diacare.26.5.1490 Zinman, 1997, Insulin lispro in CSII: Results of a double-blind crossover study, Diabetes, 46, 440, 10.2337/diab.46.3.440 Singh, 2009, Efficacy and safety of insulin analogues for the management of diabetes mellitus:Aa meta-analysis, CMAJ, 180, 385, 10.1503/cmaj.081041 Jacobsen, 2009, Evidence-based insulin treatment in type1 diabetes mellitus, Diabetes Res Clin Pract, 86, 1, 10.1016/j.diabres.2009.05.020 Sanches, 2011, Revisiting the efficacy of long-acting insulin analogues on adults with type1 diabetes using mixed-treatment comparisons, Diabetes Res Clin Pract, 94, 333, 10.1016/j.diabres.2011.09.001 Hermansen, 2006, A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type2 diabetes, Diabetes Care, 29, 1269, 10.2337/dc05-1365 Jonassen, 2012, Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin, Pharm Res, 29, 2104, 10.1007/s11095-012-0739-z Simó, 2013, Nueva insulina basal de acción ultralenta: Insulina degludec, Av Diabetol, 29, 4, 10.1016/j.avdiab.2012.11.001 Heise, 2012, Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type2 diabetes, Diabetes Obes Metab, 14, 944, 10.1111/j.1463-1326.2012.01638.x Heise, 2012, Insulin degludec: Four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type1 diabetes, Diabetes Obes Metab, 14, 859, 10.1111/j.1463-1326.2012.01627.x Ratner, 2013, Hypoglycaemia risk with insulin degludec compared with insulin glargine in type2 and type1 diabetes: A pre-planned meta-analysis of phase 3 trials, Diabetes Obes Metab, 15, 175, 10.1111/dom.12032 Heller, 2012, Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type1 diabetes (BEGIN Basal-Bolus Type1): A phase3, randomised, open-label, treat-to-target non-inferiority trial, Lancet, 379, 1489, 10.1016/S0140-6736(12)60204-9 Garber, 2012, Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type2 diabetes (BEGIN Basal-Bolus Type2): A phase 3, randomised, open-label, treat-to-target non-inferiority trial, Lancet, 379, 1498, 10.1016/S0140-6736(12)60205-0 Zinman, 2012, Insulin degludec versus insulin glargine in insulin-naive patients with type2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long), Diabetes Care, 35, 2464, 10.2337/dc12-1205 Novo Nordisk. Insulin degludec and insulin degludec/insulin aspart treatment to improve glycemic control in patients with diabetes mellitus. Briefing Information for the November 8, 2012 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. [consultado 5 Oct 2013]. Disponible en: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM327017.pdf. 2012 U.S. Food and Drug Administration. FDA Briefing Information, Insulin Degludec and Insulin Degludec/Aspart, for the November 8, 2012 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. [consultado 5 Oct 2013]. Disponible en: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM327015.pdf. 2012 Freemantle, 2013, Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with type2 diabetes starting on basal insulin: A meta-analysis of phase3a trials, Diabet Med, 30, 226, 10.1111/dme.12086 Randløv, 2008, How much do forgotten insulin injections matter to hemoglobin A1c in people with diabetes? A simulation study, J Diabetes Sci Technol, 2, 229, 10.1177/193229680800200209 Morris, 1997, Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus, Lancet, 350, 1505, 10.1016/S0140-6736(97)06234-X Cramer, 2005, The influence of insulin use on glycemic control: How well do adults follow prescriptions for insulin?, Diabetes Care, 28, 78, 10.2337/diacare.28.1.78 Peyrot, 2012, Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study, Diabet Med, 29, 682, 10.1111/j.1464-5491.2012.03605.x Donnelly, 2007, Adherence to insulin and its association with glycaemic control in patients with type2 diabetes, QJM, 100, 345, 10.1093/qjmed/hcm031 Brod, 2012, Adherence patterns in patients with type2 diabetes on basal insulin analogues: Missed, mistimed and reduced doses, Curr Med Res Opin, 28, 1933, 10.1185/03007995.2012.743458 Müller, 2013, Randomized crossover study to examine the necessity of an injection-to-meal interval in patients with type2 diabetes and human insulin, Diabetes Care, 36, 1865, 10.2337/dc12-1694 Bott, 2003, Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type1 diabetes, Diabet Med, 20, 626, 10.1046/j.1464-5491.2003.01010.x Meneghini, 2013, Diabetes Care, 36, 858, 10.2337/dc12-1668 Meneghini, 2012, Insulin degludec: A novel ultralong-acting basal insulin for use in type1 and 2 diabetes, Expert Rev Endocrinol Metab, 7, 9, 10.1586/eem.11.86 Mathieu, 2013, Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type1 diabetes (BEGIN: Flex T1): A 26-week randomized, treat-to-target trial with a 26-week extension, J Clin Endocrinol Metab, 98, 1154, 10.1210/jc.2012-3249